Medication info

Posimet Extended Release Tablet 10/500 Milligrams

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Widus Pharmaceuticals Co., Ltd.
Appearance
Pink, double convex, oval, film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202204064 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy alone: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum daily dose of 1000 mg. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Since metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Ingredients

Manufacturer
Widus Pharmaceuticals Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is administered as an adjunct to improve blood glucose control in adults with type 2 diabetes using dapagliflozin and metformin in combination. It is used in conjunction with dietary and exercise therapies and is suitable when blood glucose is not adequately controlled. Special caution is required for type 2 diabetes patients with concomitant cardiovascular diseases or risk factors regarding the risk of cardiovascular events. Please refer to the clinical trial information for healthcare professionals for more details. This medication effectively aids in treating diabetes and controlling blood glucose.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy alone: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum daily dose of 1000 mg. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Since metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Precautions

This medication is a diabetes treatment that helps control blood glucose. When taking this medication, kidney function is very important, so it should not be used in patients with reduced kidney function or kidney impairment. Additionally, it should be avoided in cases of severe infections, dehydration, cardiovascular issues, or acute illnesses. Pregnant or nursing women should not use this medication, and caution is especially needed during the 2nd and 3rd trimesters due to potential effects on kidney development. This medication may increase the risk of hypoglycemia when used with other diabetes medications, so dosage adjustments may be necessary when used with insulin or sulfonylureas. This medication can rarely induce life-threatening lactic acidosis or ketoacidosis, so if symptoms such as fatigue, muscle pain, difficulty breathing, abdominal pain, or vomiting occur, consult a doctor immediately. Furthermore, this medication may increase the risk of genital and urinary tract infections, and prompt treatment is necessary if infection symptoms occur. Patients with risks of reduced fluid volume or hypotension should periodically monitor blood pressure and fluid status, and temporarily discontinue the medication if dehydration symptoms occur. This medication is not recommended for patients with liver function impairment, and excessive alcohol consumption should also be avoided. Patients scheduled for surgery should stop taking this medication 48 hours before surgery and should resume after surgical renal function is confirmed to be normal. Elderly individuals often experience decreased kidney function, thus dosage adjustments and kidney function monitoring are necessary, particularly for those aged 80 and over, who should use this medication cautiously. In case of overdose, immediate medical attention is required, as this medication can be removed through dialysis, making rapid intervention essential. Caution should be exercised regarding dizziness while driving or operating machinery during the medication period, and it should be stored out of children’s reach.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • elevated blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensory hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Pink, double convex, oval, film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.